RxDoctor Payments Data

Jessica Tucker, APRN

Primary Care · Canton, OHNPI 1316668213

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 35 payments — averaging $37.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$329
  • AbbVie$210
  • Atricure, Inc.$105
  • Ultragenyx Pharmaceutical Inc.$95
  • Biogen$85
  • Neurelis, Inc.$76
  • plus $410 from 12 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 75th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$106
Medicare patients
16
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$49,465
JardianceEmpagliflozin41$45,335
JanuviaSitagliptin Phosphate31$28,147
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$27,640
FarxigaDapagliflozin Propanediol18$24,822
RybelsusSemaglutide14$19,072
TrulicityDulaglutide11$12,312
Breo ElliptaFluticasone/Vilanterol19$9,584
SymbicortBudesonide/Formoterol Fumarate14$7,033
Albuterol Sulfate HfaAlbuterol Sulfate130$6,049
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$3,709
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,957
Omeprazole205$2,533
Ventolin HfaAlbuterol Sulfate17$1,926
Atorvastatin Calcium265$1,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$329$59,49563 claims
GSKTrelegy Ellipta, Breo Ellipta$44$59,04954 claims
Boehringer IngelheimJardiance$31$45,33541 claims
Novo NordiskRybelsus$15$19,07214 claims
Lilly USA, LLCTrulicity$15$12,31211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 321 primary care providers in Ohio.

Other primary care in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →